

In the Claims:

Please amend claims 5, 20, 22, and 24 as follows.

5. (Amended) A method of affecting a biological process characterized by abnormal cell migration through a physiological barrier, [said] the method comprising administering the composition of claim 1 to a mammal experiencing [said] the biological process in an amount to affect [said] the biological process.

6. (Amended) The method of claim 5, wherein [said] the biological process is selected from the group consisting of angiogenesis, organogenesis, ovulation, inflammation, cancer, tumor cell invasion and metastasis, and atherosclerosis.

7. (Amended) The method of claim 5, wherein [said] the mammal is a human.

8. (Amended) A method of inhibiting PAI-1-dependent adhesion of a cell to a tissue of a mammal, [said] the method comprising administering to [said] the tissue the composition of claim 1 in an amount to inhibit adhesion of [said] the cell to [said] the tissue.

9. (Amended) The method of claim 8, wherein [said] the tissue is *in vivo* in [said] the mammal.

10. (Amended) The method of claim 8, wherein [said] the mammal is a human.

11. (Amended) A method of promoting clearance of scuPA from the surface of a mammalian cell, [said] the method comprising administering the composition of claim 1 to [said] the cell in an amount to promote clearance of [said] the scuPA from [said] the cell.

12. (Amended) The method of claim 11, wherein [said] the cell is a human cell.

13. (Amended) The method of claim 12, wherein [said] the composition is administered *in vivo* in [said] the human.

14. (Amended) A method of impeding pathological migration of a cell in a mammal, [said] the method comprising administering to [said] the mammal the composition of claim 1 in an amount effective to impede pathological migration of [said] the cell.

15. (Amended) The method of claim 14, wherein [said] the composition is administered to [said] the mammal at the site of a tumor in [said] the mammal.

16. (Amended) The method of claim 14, wherein [said] the mammal is a human.

17. (Amended) A method of inhibiting PAI-1 activity in a tissue of a mammal, [said] the method comprising administering to [said] the tissue the composition of claim 1 in an amount effective to inhibit PAI-1 activity in [said] the tissue.

18. (Amended) The method of claim 17, wherein [said] the mammal is a human.

19. (Amended) The method of claim 18, wherein [said] the composition is administered *in vivo* in [said] the human.

20. (Amended) A kit comprising a peptide having the amino acid sequence $X_1X_2X_3X_4X_5X_6X_7X_8$, wherein:

X_1 is hydrogen, an amino-terminal blocking group, or one to twenty amino acid residues;

X_2 is an amino acid selected from the group consisting of D, E, H, K, and R;

X_3 is an amino acid selected from the group consisting of E and D;